Theranostic Approach for Pancreatic Cancer

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR). Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

• 1. Biology, pathophysiology and epidemiology of pancreatic cancer2. Diagnosis of pancreatic cancer 3. Current knowledge on drug resistance and therapeutic approaches to eliminate pancreatic cancer stem cells4. Drug resistance and microenvironment in pancreatic cancer 5. The role of tumor microenvironment in the metastasis of pancreatic cancer and immunotherapy 6. Latest developments in chemotherapy for metastatic pancreatic cancer 7. Genetic manipulations with chemotherapy in pancreatic cancer 8. Genetic predisposition for pancreatic cancer9. Pancreatic cancer resistance to chemotherapy: Resensitization strategies using resveratrol10. Anti-cancer activity of a small molecule, tolfenamic acid: An emphasis on pancreatic cancer11. Targeting the epigenome as a therapeutic strategy for pancreatic tumors - Non-coding RNAs and chromatin remodelers 12. Pancreatic cancer chemoprevention: A review on molecular pathways involved in carcinogenesis and targeting with terpenoids, a new potential anti-tumor drugs13. Meta-analysis on MTHFR polymorphisms and pancreatic cancer susceptibility 14. Therapeutic vaccines for pancreatic cancer 15. Epidermal growth factor receptor role in pancreatic cancer 16. Recent advances in molecular diagnostics and therapeutic targets for pancreatic cancer